Logest 21 tablets — Made in Germany by Bayer — Free Delivery

Brand: BAYER
Product Code: Logest
Availability: In Stock

$31.67

Add to Cart

Description

Product description

Tablets "Logest®" are used for oral contraception.

Compound

One film-coated tablet contains (active ingredients):

ethinylestradiol - 20 mcg;

gestodene - 75 mcg.

Excipients: lactose, monohydrate; corn starch; povidone; magnesium stearate; sucrose; polyethylene glycol; calcium carbonate; talc; non-ionic emulsified wax.

Contraindications

Combined hormonal contraceptives (CHCs) should not be used if any of the following conditions or diseases are present. If any of these conditions occur for the first time with CHC use, the preparation should be discontinued immediately.

Presence or risk of developing venous thromboembolism (VTE):

venous thromboembolic events at present (anticoagulant therapy) or in history (for example, deep vein thrombosis (DVT) or pulmonary embolism (PE));
known hereditary or acquired tendency to thrombosis, venous thromboembolism (eg resistance to activated protein C, including factor V Leiden), antithrombin III deficiency, protein C deficiency, protein S deficiency;
major surgical interventions with prolonged immobilization;
high risk of venous thromboembolism due to the presence of multiple risk factors.

The presence or risk of developing arterial thromboembolism (ATE):

arterial thromboembolism - the presence of arterial thromboembolism at present or in history (for example, myocardial infarction (MI)) or the presence of prodromal conditions (for example, angina pectoris);
cerebrovascular disease - the presence of a stroke at present or in history, or the presence of prodromal conditions (for example, transient ischemic attack (TIA));
known hereditary or acquired tendency to arterial thromboembolism (eg hyperhomocysteinemia) or the presence of antiphospholipid antibodies (anticardiolipin antibodies, lupus anticoagulant);
migraine with a history of focal neurological symptoms;
high risk of arterial thromboembolism due to the presence of multiple risk factors or the presence of one of the serious risk factors, such as diabetes mellitus with vascular damage, severe arterial hypertension, severe dyslipoproteinemia;
current or history of severe liver disease until liver function tests return to normal;
the presence or history of liver tumors (benign or malignant);
known or suspected hormone-dependent malignant tumors (for example, genital or mammary glands);
vaginal bleeding of unknown etiology;
hypersensitivity to the active substances or to any of the components of the preparation.

"Logest®" is contraindicated for simultaneous use with preparations containing St. John's wort.

The preparation "Logest®" is contraindicated when used simultaneously with preparations containing ombitasvir / paritaprevir / ritonavir and dasabuvir.

Mode of application

Take one tablet once a day at regular intervals at about the same time (with a small amount of liquid if necessary) for 21 consecutive days.

The use of the tablet from each subsequent package should be started after the end of the seven-day break in taking the preparation. Withdrawal bleeding usually begins 2 to 3 days after the last tablet is taken and may continue after the start of the next pack of tablets.

Application features

pregnant

The preparation is contraindicated during pregnancy.

The use of the preparation "Logest®" is not recommended during breastfeeding, since estrogens / progestins penetrate into breast milk. If a woman wants to breastfeed, it is necessary to choose another method of contraception.

Children

The preparation is indicated for use as prescribed by a doctor only after the onset of regular menstruation.

Overdose

There are no reports of overdose with Logest®.

Overdose of COCs may cause symptoms such as nausea, vomiting and withdrawal bleeding. Withdrawal bleeding can occur in girls even before menarche in case of inadvertent/accidental preparation use. There are no antidotes, treatment is symptomatic.

Side effects

Women taking CHCs were at an increased risk of developing venous or arterial thrombotic/thromboembolic events, including myocardial infarction, stroke, transient ischemic attacks, venous thrombosis, and PE.

The most frequently reported side effects (> 10%) in phase III clinical trials and during post-marketing surveillance were headaches, including migraines, and spotting/spotting.

Storage conditions

Store at a temperature not exceeding 25 ° C, out of the reach of children and protected from light.

Shelf life - 3 years.

0 reviews

There are no reviews for this product.